SHBG CRISPR/Cas9 KO Plasmid (h): sc-402099
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SHBG CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SHBG genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SHBG Antibody (C-2): sc-377032
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SHBG CRISPR/Cas9 KO Plasmid (h) | sc-402099 | 20 µg | $397.00 |
Overview
Sex hormone–binding globulin (SHBG) is a secreted plasma glycoprotein that binds and transports androgens and estrogens, thereby regulating the free fraction of circulating steroids and modulating hormone availability to target tissues. By buffering steroid distribution and influencing hormone delivery to cells, SHBG contributes to endocrine homeostasis and steroid-responsive transcriptional programs that shape metabolic and reproductive physiology. Variation in SHBG expression or function has been linked to altered sex steroid bioavailability and is frequently studied in relation to metabolic traits and hormone-dependent disease biology, including dysregulated glucose–lipid metabolism and reproductive endocrine phenotypes. In vitro and in vivo models of SHBG perturbation are used to dissect mechanisms connecting steroid transport to downstream signaling networks and gene expression changes in liver and peripheral tissues.
SHBG CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SHBG gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SHBG together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SHBG open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SHBG protein expression.
This CRISPR knockout system enables efficient generation of SHBG-deficient cell models for investigation of SHBG signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SHBG exon(s) critical for SHBG function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SHBG genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SHBG CRISPR/Cas9 KO Plasmid (h) and SHBG CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SHBG locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SHBG HDR Plasmid (h) and SHBG HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SHBG homology arms to support homology-directed repair at defined SHBG target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.